| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
52,560,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of drug and delivery solutions for the treatment of patients with ear, nose, and throat, diseases. Co.'s proprietary technology platform, XTreo™, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Co.'s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure for the treatment of chronic rhinosinusitis. The therapeutic embedded within LYR-210 and LYR-220 is mometasone furoate.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
25,000 |
7,246,664 |
7,254,492 |
| Total Buy Value |
$0 |
$74,095 |
$17,848,416 |
$17,887,102 |
| Total People Bought |
0 |
1 |
4 |
5 |
| Total Buy Transactions |
0 |
1 |
4 |
7 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Waksal Harlan |
Executive Chair |
• • – |
2024-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
275,000 |
536,966 |
|
- |
|
| Waksal Harlan |
Executive Chair |
• • – |
2023-11-10 |
4 |
B |
$2.96 |
$74,095 |
D/D |
25,000 |
261,966 |
0.01 |
- |
|
| North Bridge Venture Management Vi, L.p. |
10% Owner |
– – • |
2023-05-31 |
4 |
B |
$2.43 |
$4,387,161 |
I/I |
1,805,416 |
2,521,745 |
1.5 |
- |
|
| Edelman Joseph |
Director |
– • • |
2023-05-31 |
4 |
B |
$2.49 |
$8,999,999 |
I/I |
3,610,832 |
11,469,117 |
2.25 |
- |
|
| Anderson Edward T |
Director |
– • • |
2023-05-31 |
4 |
B |
$2.43 |
$4,387,161 |
I/I |
1,805,416 |
2,521,745 |
2.25 |
- |
|
| Noyes Corinne |
See Remarks |
• – – |
2023-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
36,667 |
36,667 |
|
- |
|
| Richard Robert E. |
SVP, Technical Operations |
• – – |
2023-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
30,000 |
|
- |
|
| Merrifield C Ann |
Director |
– • – |
2022-06-10 |
4 |
B |
$5.05 |
$20,200 |
D/D |
4,000 |
11,328 |
2.39 |
- |
|
| Merrifield C Ann |
Director |
– • – |
2022-05-16 |
4 |
B |
$5.00 |
$1,640 |
D/D |
328 |
7,328 |
2.31 |
- |
|
| Merrifield C Ann |
Director |
– • – |
2022-05-13 |
4 |
B |
$4.81 |
$16,846 |
D/D |
3,500 |
7,000 |
2.39 |
- |
|
| North Bridge Venture Management Vi, L.p. |
10% Owner |
– – • |
2022-04-12 |
4 |
B |
$4.22 |
$9,999,995 |
I/I |
2,369,667 |
1,318,133 |
1.5 |
- |
|
| Anderson Edward T |
Director |
– • • |
2022-04-12 |
4 |
B |
$4.22 |
$499,998 |
D/D |
118,483 |
118,483 |
3.92 |
- |
|
| Anderson Edward T |
Director |
– • • |
2022-04-12 |
4 |
B |
$4.22 |
$9,999,995 |
I/I |
2,369,667 |
1,318,133 |
2.25 |
- |
|
| Edelman Joseph |
Director |
– • • |
2022-04-12 |
4 |
B |
$4.22 |
$24,999,997 |
I/I |
5,924,170 |
7,858,285 |
2.25 |
- |
|
| Waksal Harlan |
Executive Chair |
• • – |
2022-04-12 |
4 |
B |
$4.22 |
$999,997 |
D/D |
236,966 |
236,966 |
2.81 |
- |
|
| Merrifield C Ann |
Director |
– • – |
2021-06-17 |
4 |
B |
$8.97 |
$31,395 |
D/D |
3,500 |
3,500 |
2.39 |
- |
|
| Snyderman Nancy Lynn Md |
Director |
– • – |
2020-12-16 |
4 |
B |
$9.72 |
$9,963 |
D/D |
1,025 |
1,025 |
2.39 |
- |
|
| Edelman Joseph |
Director |
– • • |
2020-05-05 |
4 |
B |
$16.00 |
$10,000,000 |
I/I |
625,000 |
1,934,115 |
2.25 |
- |
|
| Levy Guy |
10% Owner |
– – • |
2020-05-05 |
4 |
B |
$16.00 |
$2,480,000 |
I/I |
155,000 |
155,000 |
1.5 |
- |
|
| Levy Guy |
10% Owner |
– – • |
2020-05-05 |
4 |
S |
$16.00 |
$270,544 |
I/I |
(16,909) |
457,421 |
|
- |
|
| Levy Guy |
10% Owner |
– – • |
2020-05-05 |
4 |
OE |
$8.63 |
$270,827 |
I/I |
31,382 |
474,330 |
|
- |
|
| Levy Guy |
10% Owner |
– – • |
2020-05-05 |
4 |
A |
$0.00 |
$0 |
I/I |
442,938 |
442,948 |
|
- |
|
| Anderson Edward T |
Director |
– • • |
2020-05-05 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
553,123 |
2.25 |
- |
|
| Anderson Edward T |
Director |
– • • |
2020-05-05 |
4 |
S |
$16.00 |
$386,928 |
I/I |
(24,183) |
478,123 |
|
- |
|
| Anderson Edward T |
Director |
– • • |
2020-05-05 |
4 |
OE |
$8.63 |
$386,892 |
I/I |
44,831 |
485,378 |
|
- |
|
46 Records found
|
|
Page 1 of 2 |
|
|
